Intravenous Immunoglobulin Treatment in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: a Double Blind, Placebo Controlled Study

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1993 Jan 1

PMID 8429321

Citations 54

Authors

M Vermeulen

P A van Doorn

A Brand

P F Strengers

F G Jennekens

H F BUSCH

Affiliations

Soon will be listed here.

Abstract

Patients with a clinical diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) were randomised in a double-blind, placebo-controlled multicentre trial to investigate whether high-dose intravenous immunoglobulin treatment (IVIg) for 5 consecutive days has a beneficial effect. Fifteen patients were randomised to IVIg and 13 to placebo. In the IVIg treatment group 4 patients improved and 3 patients in the placebo group. The degree of improvement of the patients in the IVIg treatment group was no different from the patients in the placebo group. Electrophysiological studies did not show significant differences between the groups. Since a previously performed cross-over trial showed that a selected group of CIDP patients responded better to IVIg than to placebo, it is concluded that we need better criteria to select CIDP patients for treatment with IVIg.

Citing Articles

Association Between MScanFit Motor Unit Number Estimation and Clinical Function and Response to Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.

Hansen P, Mohammed A, Markvardsen L, Andersen H, Tankisi H, Sindrup S J Peripher Nerv Syst. 2025; 30(1):e70001.

PMID: 39887824 PMC: 11783579. DOI: 10.1111/jns.70001.

Long-term follow-up of relapse and remission of CIDP in a Chinese cohort.

Niu J, Zhang L, Hu N, Cui L, Liu M BMJ Neurol Open. 2024; 6(1):e000651.

PMID: 38770161 PMC: 11103238. DOI: 10.1136/bmjno-2024-000651.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks.

Rajabally Y Immunotargets Ther. 2024; 13:99-110.

PMID: 38435981 PMC: 10906673. DOI: 10.2147/ITT.S388151.

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Bus S, de Haan R, Vermeulen M, van Schaik I, Eftimov F Cochrane Database Syst Rev. 2024; 2:CD001797.

PMID: 38353301 PMC: 10865446. DOI: 10.1002/14651858.CD001797.pub4.

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Dalakas M Neurotherapeutics. 2021; 18(4):2397-2418.

PMID: 34766257 PMC: 8585501. DOI: 10.1007/s13311-021-01108-4.

References

Dalakas M, Engel W . Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol. 1981; 9 Suppl:134-45. DOI: 10.1002/ana.410090719. View

Dyck P, OBrien P, Oviatt K, DINAPOLI R, Daube J, Bartleson J . Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982; 11(2):136-41. DOI: 10.1002/ana.410110205. View

Vermeulen M, van der Meche F, Speelman J, Weber A, BUSCH H . Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985; 70(3):317-26. DOI: 10.1016/0022-510x(85)90173-x. View

Dyck P, Daube J, OBrien P, Pineda A, Low P, Windebank A . Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986; 314(8):461-5. DOI: 10.1056/NEJM198602203140801. View

Albala M, McNamara M, Sokol M, Wyshock E . Improvement of neurologic function in chronic inflammatory demyelinating polyradiculoneuropathy following intravenous gamma-globulin infusion. Arch Neurol. 1987; 44(3):248-9. DOI: 10.1001/archneur.1987.00520150004002. View

Curro Dossi B, Tezzon F . High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Ital J Neurol Sci. 1987; 8(4):321-6. DOI: 10.1007/BF02335733. View

Austin J . Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain. 1958; 81(2):157-92. DOI: 10.1093/brain/81.2.157. View

Faed J, Day B, Pollock M, Taylor P, NUKADA H, Hammond-Tooke G . High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 1989; 39(3):422-5. DOI: 10.1212/wnl.39.3.422. View

van Doorn P, Brand A, Strengers P, Meulstee J, Vermeulen M . High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990; 40(2):209-12. DOI: 10.1212/wnl.40.2.209. View

10.

van Doorn P, Vermeulen M, Brand A, Mulder P, BUSCH H . Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991; 48(2):217-20. DOI: 10.1001/archneur.1991.00530140113024. View

11.

Cornblath D, Chaudhry V, Griffin J . Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991; 30(1):104-6. DOI: 10.1002/ana.410300119. View

12.

Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P . Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol. 1992; 49(6):612-6. DOI: 10.1001/archneur.1992.00530300044009. View

13.

van Swieten J, Koudstaal P, Visser M, Schouten H, van Gijn J . Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19(5):604-7. DOI: 10.1161/01.str.19.5.604. View